よむ、つかう、まなぶ。
06【参考資料１】Interim statement on the composition of current COVID19 vaccines World Health Organization 17 June 2022 (3 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1
(1) at levels that remain acceptable (2).
2
3
Nevertheless, there has been substantial virus evolution, particularly in the S
4
protein, since the first cases of COVID-19 and it is likely that this evolution will
5
continue, resulting in the emergence of new variants in the future. There is
6
uncertainty about the timing of the emergence, extent of global circulation and
7
antigenic characteristics of future variants. In this context, immunity elicited
8
against as broad a range of SARS-CoV-2 S protein antigens as possible may be
9
desirable to retain and potentially improve protection against future variants.
10
Therefore, it may be prudent to pursue an additional objective of COVID-19
11
vaccination to achieve immune responses that both:
12
・elicit a greater breadth in the immune response against circulating and emerging
13
14
15
variants, to enhance protection against these variants; and
・ retain protection against hospitalization, severe disease and death, and
protecting health systems.
16
17
As such, a modified COVID-19 vaccine composition may be warranted to broaden
18
immune protection against divergent SARS-CoV-2 S protein antigens.
19
20
If a modified COVID-19 vaccine composition is deemed to be necessary, what is
21
the recommended strain composition of the vaccine?
22
The TAG-CO-VAC has considered the comparative epidemiological and
23
virological characteristics of VOCs to date, including Omicron. This included, but
24
was not limited to, published and unpublished data on the antigenic
25
characteristics and antibody escape of various VOCs including Omicron, the
26
cross-protection of Omicron specific responses following vaccination or infection
27
with prior VOCs, and following Omicron infection and/or Omicron-specific
28
vaccine candidates (see Annex). Importantly, the TAG-CO-VAC acknowledges
29
that at this time, limited animal model and human data have been published on
30
Omicron-specific vaccine candidates, and these will continue to be reviewed as
31
more data become available.
32
3
(1) at levels that remain acceptable (2).
2
3
Nevertheless, there has been substantial virus evolution, particularly in the S
4
protein, since the first cases of COVID-19 and it is likely that this evolution will
5
continue, resulting in the emergence of new variants in the future. There is
6
uncertainty about the timing of the emergence, extent of global circulation and
7
antigenic characteristics of future variants. In this context, immunity elicited
8
against as broad a range of SARS-CoV-2 S protein antigens as possible may be
9
desirable to retain and potentially improve protection against future variants.
10
Therefore, it may be prudent to pursue an additional objective of COVID-19
11
vaccination to achieve immune responses that both:
12
・elicit a greater breadth in the immune response against circulating and emerging
13
14
15
variants, to enhance protection against these variants; and
・ retain protection against hospitalization, severe disease and death, and
protecting health systems.
16
17
As such, a modified COVID-19 vaccine composition may be warranted to broaden
18
immune protection against divergent SARS-CoV-2 S protein antigens.
19
20
If a modified COVID-19 vaccine composition is deemed to be necessary, what is
21
the recommended strain composition of the vaccine?
22
The TAG-CO-VAC has considered the comparative epidemiological and
23
virological characteristics of VOCs to date, including Omicron. This included, but
24
was not limited to, published and unpublished data on the antigenic
25
characteristics and antibody escape of various VOCs including Omicron, the
26
cross-protection of Omicron specific responses following vaccination or infection
27
with prior VOCs, and following Omicron infection and/or Omicron-specific
28
vaccine candidates (see Annex). Importantly, the TAG-CO-VAC acknowledges
29
that at this time, limited animal model and human data have been published on
30
Omicron-specific vaccine candidates, and these will continue to be reviewed as
31
more data become available.
32
3